“Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 Years and Older With and Without Atopic Comorbidities”. 2024. SKIN The Journal of Cutaneous Medicine 8 (1): s322. https://doi.org/10.25251/skin.8.supp.322.